11β-HSD1 modulates LPS-induced innate immune responses in adipocytes by altering expression of PTEN

Molecular Endocrinology
Wenfang LaiGuizhu Hong

Abstract

Inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) represents a therapeutic target for treating hyperglycemia in type 2 diabetes. Here, we investigate the effects of 11β-HSD1 on the innate immune response of adipocytes to produce proinflammatory cytokines. The 11β-HSD1 inhibitor emodin, or 11β-HSD1-targeted small interfering RNA, dose dependently suppressed IL-6, IL-1β, and TNF-α expression in lipopolysaccharide-treated 3T3-L1 adipocytes. Inhibiting 11β-HSD1 also reduced phosphatase and tensin homologue (PTEN) expression, a negative regulator of phosphatidylinositol 3-kinase effects, whereas 1pM cortisone or dexamethasone induced IL-6 and PTEN levels. PTEN-targeted small interfering RNA decreased IL-6, IL-1β, and TNF-α without affecting 11β-HSD1 levels. Correspondingly, emodin increased phosphorylated protein kinase B (p-PKB) (Ser473) to PKB ratio but not p-PKB (Thr308) to PKB ratio. Emodin did not increase the p-PKB (Ser473) to PKB ratio when the rapamycin-insensitive companion of mTOR was depleted, further supporting the involvement of mammalian target of rapamycin complex 2 in PKB phosphorylation. Moreover, emodin suppressed phosphorylated inhibitor of κB α (p-IκBα) to IκBα ratio and reduced nuclear factor κ B ...Continue Reading

References

Jul 25, 1997·Cell·C H RégnierM Rothe
Jun 9, 1998·The Journal of Steroid Biochemistry and Molecular Biology·A NapolitanoK E Chapman
Apr 5, 2001·American Journal of Physiology. Endocrinology and Metabolism·P A KernG Ranganathan
Jul 24, 2001·JAMA : the Journal of the American Medical Association·A D PradhanP M Ridker
Jan 5, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jerome GalonStefan R Bornstein
May 22, 2003·Neuroimmunomodulation·Denis FranchimontGeorge Chrousos
Jul 5, 2003·The Journal of Clinical Investigation·Robert S GarofaloKevin G Coleman
Aug 14, 2003·The Journal of Clinical Endocrinology and Metabolism·Deborah J WakeBrian R Walker
Aug 19, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Guizhu HongJohn Brown
Apr 22, 2004·American Journal of Physiology. Renal Physiology·Nicolas MarkadieuRenaud Beauwens
Jul 10, 2004·Acta Anaesthesiologica Scandinavica·M P YeagerA U Munck
Dec 18, 2004·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Kolapo M Ajuwon, Michael E Spurlock
Feb 19, 2005·Science·D D SarbassovDavid M Sabatini
Mar 4, 2005·Molecular and Cellular Biology·Christine Kurlawalla-MartinezHong Wu
Aug 17, 2005·The Journal of Experimental Medicine·Anne Hermanowski-VosatkaRolf Thieringer
Jul 11, 2006·The Journal of Clinical Investigation·Steven E ShoelsonAllison B Goldfine
Oct 21, 2006·The Journal of Clinical Investigation·Hang ShiJeffrey S Flier
Nov 9, 2006·American Journal of Physiology. Endocrinology and Metabolism·S J CreelyS Kumar
Dec 15, 2006·Nature·Gökhan S Hotamisligil
Apr 26, 2007·Diabetes·Patrice D CaniRémy Burcelin
Oct 5, 2010·Journal of Leukocyte Biology·Philipp GünzlGernot Schabbauer
Oct 14, 2010·Journal of Dental Research·J BrownM Martin
Nov 26, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Edward A MedinaMichael T Berton

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.